Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dan'e Xiaoliu Granules is a Traditional Chinese Medicine (TCM) formulation developed by Jiangsu Jichuan Pharmaceutical for the treatment of uterine fibroids. It is specifically indicated for patients presenting with the "phlegm and blood stasis" syndrome (痰瘀互结证). The formulation typically contains herbal extracts aimed at promoting blood circulation, resolving stasis, and softening hardness to dissipate masses. Clinical development, including Phase 2 trials such as CTR20132715, has focused on evaluating the safety and efficacy of different dosages in reducing the volume of uterine leiomyomas and improving associated clinical symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dan'e Xiaoliu Granules.